Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. - Wikidata - wikimedia - TriplyDB

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

http://www.wikidata.org/entity/Q34749618

about

Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Cardioprotective Potentials of Plant-Derived Small Molecules against Doxorubicin Associated Cardiotoxicity Isorhamnetin attenuates atherosclerosis by inhibiting macrophage apoptosis via PI3K/AKT activation and HO-1 induction Ginkgolide B Exerts Cardioprotective Properties against Doxorubicin-Induced Cardiotoxicity by Regulating Reactive Oxygen Species, Akt and Calcium Signaling Pathways In Vitro and In Vivo Effects of Polyphenols on Oxidative Stress-Mediated Injury in Cardiomyocytes.Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention Metabolic profiles of the Flos Abelmoschus manihot extract by intestinal bacteria from the normal and CKD model rats based on UPLC-Q-TOF/MS.Natural Compounds as Occult Ototoxins? Ginkgo biloba Flavonoids Moderately Damage Lateral Line Hair Cells.Myricitrin Protects against Doxorubicin-Induced Cardiotoxicity by Counteracting Oxidative Stress and Inhibiting Mitochondrial Apoptosis via ERK/P53 Pathway.A comparison of replicative senescence and doxorubicin-induced premature senescence of vascular smooth muscle cells isolated from human aorta.Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.Myricitrin Attenuates High Glucose-Induced Apoptosis through Activating Akt-Nrf2 Signaling in H9c2 Cardiomyocytes.A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells.The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.The Metabolic Profiling of Isorhamnetin-3-O-Neohesperidoside Produced by Human Intestinal Flora Employing UPLC-Q-TOF/MS.Flavonol regulation in tumor cells.All-trans-retinoic acid ameliorates doxorubicin-induced cardiotoxicity: in vivo potential involvement of oxidative stress, inflammation, and apoptosis via caspase-3 and p53 down-expression.Protection of Luteolin-7-O-Glucoside Against Doxorubicin-Induced Injury Through PTEN/Akt and ERK Pathway in H9c2 Cells.Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.Protective effect of proanthocyanidins against doxorubicin-induced nephrotoxicity in rats.Treatment with Isorhamnetin Protects the Brain Against Ischemic Injury in Mice.Chemical Composition and Biological Prospects of Essential Oils and Extracts of Aphyllocladus spartioides Growing in Northwest Argentina.Protection of Luteolin-7-O-glucoside against apoptosis induced by hypoxia/reoxygenation through the MAPK pathways in H9c2 cells.Actinidia chinensis planch polysaccharide protects against hypoxia‑induced apoptosis of cardiomyocytes in vitro.Protecting the heart in cancer therapy Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview

P2860

Q26742059-22BC9F08-AC25-488B-843C-D038A917091D Q26744634-9241577E-92B2-4F53-9914-D9AF0CFBB0F7 Q28544863-382BB665-6A6C-4C5C-8A79-CF99F1AD2F99 Q32183971-A69BBAFC-4F19-4CF8-AC46-9F77A12C8983 Q33749642-C6DEB508-D5D2-4597-98BB-2838C98A8D93 Q35788081-5BAFF596-1E48-4259-8715-407521A59CBF Q36083933-883CD280-064D-4515-A0E1-4927D979CDE7 Q36206401-F8B37789-27B0-4A52-8E83-606E432AEF6C Q37290281-9B308DCE-90A4-4D0A-95F5-63F72C24F9AF Q37526285-273541E1-0208-44F4-8F18-68C83B9843ED Q38737034-6D25300B-7A82-49CE-B31D-7FFDCB093E0D Q38758869-3B142D9E-4E50-4407-88E3-B680ACA832E7 Q38865730-B3484645-7F2B-4BA8-BC08-B655BC5DAA54 Q38875916-2F886A03-D7A5-42BC-ABF2-408B08FFC47F Q38972944-97C9CB18-A526-4F66-A2D7-D11986FF1DFD Q39157951-8266D4CC-BBCB-4D6F-8E09-C786DA10E93E Q41443826-B4F834D8-9E0C-415F-B1E8-1B151CF04959 Q46594579-163793AA-5CB2-4637-AA60-767BB02E9A17 Q46766531-91610166-5609-47C5-A2D8-C5CB6AF35722 Q47872090-3603E4B9-19D8-401A-A32D-0BC27ADE50AA Q48318998-B9B1C4D1-A445-4DD1-BE6E-E3E9803F236B Q48752367-3904316F-08AB-4918-9F1E-BAF2A5F75B92 Q50981403-13D2565D-10CB-4F1F-BE49-80504CB5F372 Q52641299-7CE668C3-237F-4F31-BC10-9EE7E49D44E3 Q54110598-269EB647-DD05-41E3-ACD8-DB0168ACA525 Q57821006-F2BA2799-38A1-49D6-A577-269093AD97D5 Q58702473-503894D3-A767-4DF2-94D5-5CFF644E854E

P2860

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

http://www.wikidata.org/entity/Q34749618

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@ast

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@en

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@nl

type

label

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@ast

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@en

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@nl

prefLabel

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@ast

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@en

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@nl

P1433

Q34749618-DC57479F-2786-4CDE-AF3A-03EF4BB7DCD0

P1476

Q34749618-9C3EF882-ACAF-41BC-8A62-B701722FEB2C

P2093

Q34749618-21431791-34E7-407A-81F6-0A5C46A9B776

Q34749618-56D26DAB-F2F9-4C46-A9F3-167489606510

Q34749618-651A1020-B1F9-4E16-9474-584A61AA7D88

Q34749618-6C980FA4-D822-4774-9C5B-9D4C7B3DD2EE

Q34749618-7EDA4523-912C-4898-A3D5-905BA53E541A

Q34749618-84969F48-0078-44A7-8E80-5D9B49540BDA

Q34749618-9811AADA-999E-4E36-9E4D-060F42583EF8

Q34749618-9AC38815-BDC5-478D-8FE4-0B35079051AD

Q34749618-B370A21D-D1F3-482D-A6BE-09ED38B7E5C8

Q34749618-BB469486-C9D5-4785-89D1-EE10F0364D9D

P2860

Q34749618-040D5DBA-DA26-4B7F-A36F-376A1A5A9202

Q34749618-0B8E1E11-53B8-4086-8DE6-AEBB881F9FA4

Q34749618-0F3BF9EA-56A2-4598-AE2E-B25469FA0131

Q34749618-140F190D-DD6B-406E-B744-A6096E63F34D

Q34749618-1B297EA2-6EC4-4BC9-AC9A-0DB602FF8FB3

Q34749618-24297337-CBB5-4EE4-8CA8-93FC197893C1

Q34749618-2C01EB49-0E17-4435-82E1-B9E8BAB4B014

Q34749618-2FFCE05A-4436-43CE-A545-730117A81F17

Q34749618-35B7B8FF-557B-4177-9B05-A41F50A7ED14

Q34749618-3799BA13-FF5D-48BF-B12E-2EE8FB380A01

P304

Q34749618-3BD801EF-B4C2-4DEF-AC3F-F48B1D05254C

P31

Q34749618-D798F9F8-F1F0-4684-A64A-359176BF2C78

P356

Q34749618-2C6EE031-CB91-452F-92F4-F54D99E8F089

P407

Q34749618-4C23CD1E-5963-4112-9CC6-561EBBB53C27

P433

Q34749618-9228539E-9EE9-4CC1-B1B5-A67E3CFBA359

P478

Q34749618-3C6C541F-23A2-4EC9-A328-54C95B6713E7

P577

Q34749618-CC960729-4C0D-4025-8DAA-9C21CF515332

P5875

Q34749618-EDA7770A-968F-445E-99AD-7915AF3D2D48

P698

Q34749618-44E73CF2-4874-405C-A18D-B729C4D192E9

P932

Q34749618-F6C3520A-04C0-4512-AAE6-5BC3ED3AA54A

P356

JOURNAL.PONE.0064526

P1433

P1476

Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

@en

P2093

Bo Ma

http://www.w3.org/2001/XMLSchema#string

Dayong Cai

http://www.w3.org/2001/XMLSchema#string

Guibo Sun

http://www.w3.org/2001/XMLSchema#string

Hongwei Wang

http://www.w3.org/2001/XMLSchema#string

Jing Sun

http://www.w3.org/2001/XMLSchema#string

Meng Qin

http://www.w3.org/2001/XMLSchema#string

Min Wang

http://www.w3.org/2001/XMLSchema#string

Peng Guo

http://www.w3.org/2001/XMLSchema#string

Xiangbao Meng

http://www.w3.org/2001/XMLSchema#string

Xiaobo Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Cardioprotective interventions for cancer patients receiving anthracyclines

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Reactive oxygen species, cellular redox systems, and apoptosis

Hexavalent chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation of Bcl-2 members, ERK1/2 and p53

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

The Bcl2 family: regulators of the cellular life-or-death switch

Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury.

Cholesterol Perturbation in Mice Results in p53 Degradation and Axonal Pathology through p38 MAPK and Mdm2 Activation.

Cardiomyocyte death in doxorubicin-induced cardiotoxicity

Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation.

P304

e64526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0064526

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236978611

http://www.w3.org/2001/XMLSchema#string

P698

23724057

http://www.w3.org/2001/XMLSchema#string

P932

3665796

http://www.w3.org/2001/XMLSchema#string